All experiments were performed in accordance with the Memorial Sloan Kettering Institutional Animal Care and Use Committee (IACUC) under protocol number 11‐06‐012. Doxycycline was administered via food pellets (625 mg·kg−1) (Harlan Teklad). 4‐Hydroxytamoxifen (4OHT, Sigma Aldrich, St. Louis, MO, USA, 70% Z‐isomer) was delivered by a single intraperitoneal injection (0.5 mg/mouse) at 5–6 weeks of age. LSL‐Kras (B6.129S4‐Krastm4Tyj/J) and Lgr5‐CreER (B6.129P2‐Lgr5tm1(cre/ERT2)Cle/J) animals were purchased from Jackson Laboratories. CAGs‐LSL‐rtTA3 (B6. Cg‐Gt(ROSA)26Sortm1(CAG‐rtTA3)Slowe/LdowJ) and TG‐Apc.3374 (Col1a1tm4(tetO‐GFP/RNAi:Apc)Slowe) mice were described previously [27 (link), 28 (link)]. We used a GEMM in which the Apc gene can be conditionally suppressed using a doxycycline‐regulated shRNA to develop colon tumors (shApc/Kraswt mice), as described previously [27 (link), 28 (link)]. A KRAS‐mt line was developed by crossing conditional KRAS‐mt allele‐carrying mice (LSL‐KrasG12D) with the shApc mice to develop shApc/KrasG12D mice. Mouse colonic organoids were isolated as previously published [28 (link)].
Free full text: Click here